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Total Events BG < 70 mg/dL 
per Sulfonylurea Induced 
Hypoglycemia  
2.85 2.5 
Proposed Removal of Sulfonylureas From Hospital 
Formulary 
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Conclusion: 
        The importance of this proposal is to reduce hypoglycemic risk. Hypoglycemia 
can be fatal, cause brain death, lead to confusion, loss of consciousness, and result in 
seizures (Vigersky, 2013). By removing and/or reducing sulfonylurea use in the 
hospital setting one may minimize this risk.  
       This research indicates that we are not maximizing the quality of care provided by 
keeping these drugs on formulary. Moreover, increased costs begin to become a 
concern when one episode of hypoglycemia increases the length of stay by 2.8 days 
(Turchin 2009). Consequently, two of the three “Triple Aim” aspects are not met while 
this drug is available for use. 
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Hypoglycemia Algorithm Proposed Revision 
An LVHN diabetes management quality improvement goal:  
Reduce Hypoglycemic Rates 
 
Sulfonylureas on Lehigh Valley Health Network Formulary  
-Glimepiride (Amaryl) 
-Glyburide (Micronase/Diabeta) 
-Glipizide XL  
-Glyburide micronized (Glynase) 
-Glipizide 
-Glipizide/Metformin  
Glycemic Control Recommendations  
   
Dear Provider,    
Your patient’s Blood Glucose values have been out of the recommended target BG range (70-180).   
Please review the selected recommendations to improve your patient’s glucose control.  
 
Patient Name: _________________________________   MR: ___________________  A ge: ___________ 
Room#: ___________Attending: __________________  Chart Review Date/Time: ___________________  
 
HbA1C:_______  EAG ________ Date________; Most Recent Creatinine:______GFR______Date_______ 
Current Weight________kg; BMI___________ 
 
Recommendations based on Glucose Trends in Graph Below:    





















THIS FORM IS NOT A PERMANENT CHART FORM 
REVIEWER USE ONLY 
 
Admit Date/Primary Admit Reason:    Prior Hospitalization Within Past 12 Months:  □ No □ Yes 





Home Diabetes Regimen: ⁯ N/A   Present Diabetes Regimen:   
□ Lantus ____units_________; □ ___________units______ 
□ Humalog ISF of ___mg/dl AC; ______ mg/dl HS; ___Q6  
□ Humalog 1 unit for ___gms CHO  
□ _______________mg ______ 
□ _______________mg ______    
































































































A. A1C: Measures glycosylated 
hemoglobin, target is less than 7% 
B. Creatinine: Provides insight on 
kidney function, generally 1.4 mg/dL or 
higher issues concern 
C. Steroids: Increases BG, if tapering off 
should also see decrease in insulin use 
D. Lantus: Long acting insulin, basal 
insulin 
E. Humalog ISF: Insulin adjusting for 
out of range BG, correctional insulin 
F. Humalog: Insulin provided that 
correlates with carbohydrate ingestion 
during meals, nutritional insulin 
G. Other drugs prescribed for diabetes: 
Prandin, Tradjenta, Humalog 75/25, 
70/30 Insulin, Insulin U-500, NPH,  IV 
Insulin, Sulfonylureas, Glucophage, 
Actos 
H. Type of nutritional plan for each 
patient, concentrating on if the patient 
has a constant carbohydrate moderate 
diet 
Note: All patients have diabetes 
Chart Review and Data Entry 
Notes: -All patients had diabetes, 18 years of age or older, and were non-pregnant 
           -Data collected was from LVHN inpatient admissions from July 2013-March 2014  
Background:  
        One of the major concerns with sulfonylurea utilization in the hospital are their 
extremely long half-lives of 16-24 hours, resulting in prolonged hypoglycemia 
(Barrueto, 2010). This is especially the case in patients with acute or chronic renal 
issues, and patients with altered nutritional intake (such as NPO and loss of appetite) 
(Vigersky, 2013) (Clement, 2013).  
        Duesenberry CM and colleagues completed a study observing adults who took a 
sulfonylurea during their hospitalization. They found that 19% of patients ingesting a 
sulfonylurea also had one or more incidents of hypoglycemia during their stay 
(Duesenberry, 2012). Adrian Jennings did a similar study spanning six months in 
which 41 out of 203 hospital patients (20.3%) on a sulfonylurea experienced 
symptoms of hypoglycemia (Jennings, 1989).  
        It has been documented and confirmed that three other hospitals have officially 
removed sulfonylureas from their drug formularies to some degree. They include 
Memorial Sloan-Kettering Cancer Center, Spectrum Health System, and Redland 
Community Hospital. 
Methods:  
        The study was conducted in two major portions, literature reviews and data 
collection. The first step in the process was evaluating scholarly work that attempted 
to make the public mindful of the risks that are associated with sulfonylurea use in an 
hospital setting. Subsequently, posts made by certified diabetes educators on the 
American Association of Diabetes Educators website were examined, networking 
with educators that have removed sulfonylureas from hospital formularies, or those 
in the process of doing so.  
        The number of patients from LVHN that ingested a sulfonylurea during their 
inpatient stay from July 2013-March 2014 was collected. In addition, all patients that 
had at least one hypoglycemic event during their hospitalization from July 2013 - 
March 2014 were also collected. The number of days and events each patient was 
hypoglycemic was also provided. By the use of excel one was able to match patient 
account numbers between the two lists. This produced data on patients that were 
prescribed a sulfonylurea and experienced at least one hypoglycemic event. 
Results: 
        The American Diabetes Association defines hypoglycemia as a blood glucose 
level less than 70 mg/dL (Moghissi, 2009). Both LVHN campuses, Cedar Crest and 
Muhlenberg, had a significantly high percent of patients with sulfonylurea induced 
hypoglycemia, 18.7 and 16.2 respectively. Producing data that corresponds with 
other sulfonylurea-induced hypoglycemic scholarly work indicates that this matter is 
prevalent at Lehigh Valley Health Network. Additionally, both hospitals had 
substantial ratios of total days and events blood glucose less than 70 mg/dL 
stimulated by a sulfonylurea. At the Cedar Crest campus these were 1.73 and 2.8, and 
1.53 and 2.5 at Muhlenberg campus respectively. 
*See handout for contraindications and precautions for each drug 
Levofloxacine AKA Levaquin: class of fluoroquinolone, an antibiotic (Kanbay, 2009) 
 
-FDA acknowledges it can cause changes in blood sugar while also taking oral anti-diabetes 
agents or insulin (Medication Guide Levaquin 2008). 
 
- “If you have diabetes and you get low blood sugar while taking Levaquin, stop taking Levaquin 
and call your healthcare provider right away” (Medication Guide Levaquin 2008) 
 
-Mechanism of fluoroquinolones glycemic irregularities is not distinctly known 
 
-What is known is that there are many reports of fluoroquinolone-induced hypoglycemia 
 
- There are also few reports of hyperglycemia created by fluoroquinolones  
 
2 possible mechanisms of fluoroquinolon-induced hypoglycemia: 
1. Pharmakinetics mechanism: 
Proposed drug–drug interaction 
Between fluoroquinolones and antihyperglycemic medications 
Gatifloxacin, Ciprofloxacin, and Levofloxacin with Glyburide (most common), Glimepiride, 
pioglitazone (with glyburide), and repaglinide  
Common system to be affected by a drug-drug interaction is a system called cytochrome P-450 
isoenzyme system 
System which oxidizes in the liver and kidneys 
One of the isoenzymes is CYP2C9, metabolizes glyburide, glimepiride, and glipizide 
The fluroroquinolones interact with the CYP isoenzymes inhibiting the oral agents metabolism 
Preventing the clearance and thereby inducing hypoglycemia 
Author admits this is an unlikely mechanism 
 
2. Pharmadynamic- 
Over-stimulated beta cells in the pancreas is the more practical mechanism for fluoroquinolone-
induced hypoglycemia 
Potassium channels play a major role in allowing the islet cells of the pancreas to secrete insulin 
If and when these channels get blocked, it causes the cell to depolarize. Consequently, voltage-
sensitive calcium channels are opened and calcium will rush into the cell; thereby ‘activating’ the 
beta cells.  
A release of insulin and decrease blood glucose will follow 
Fluoroquinolones inhibit the potassium channels in the beta cell’s membrane. Thus maintaining 
the activation of the cell and continual insulin secretions.  
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Levaquin Induced 
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